Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
University Health Network · University of Toronto · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
477
total citations
- FWCI
- 21.69
- Percentile
- 100%
- References
- 34
Citations per year
Authors
26- SVScott V. BratmanCorresponding
University Health Network, University of Toronto, Princess Margaret Cancer Centre
- SCS.Y. Cindy Yang
University Health Network, University of Toronto, Princess Margaret Cancer Centre
- MIMarco Iafolla
University Health Network, University of Toronto, Princess Margaret Cancer Centre
- ZLZhihui Liu
University Health Network, University of Toronto, Princess Margaret Cancer Centre, Public Health Ontario
- ARAaron R. Hansen
University Health Network, University of Toronto, Princess Margaret Cancer Centre
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Oncology
- Internal medicine
- Biomarker
- Circulating tumor DNA
- Clinical trial
- Response Evaluation Criteria in Solid Tumors
No related works found for this paper.